Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

The SF3B1 K666 Hotspot Mutation Confers Unfavourable Disease Risk across Major Myeloid Neoplasm Subgroups

Jennifer O Sullivan, Amy Wood, Sean Wen, Angela Hamblin, Sonia Fox, Christina Yap, Mary Frances McMullin, Nicholas C. P. Cross, Claire N Harrison, Adam J Mead

Blood (2023) 142 (Supplement 1): 4552.

https://doi.org/10.1182/blood-2023-185043

Published: 2023

Journal Articles

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

Blood (2023) 142 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2023-181521

Published: 2023

Journal Articles

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Blood (2019) 134 (26): 2388–2398.

https://doi.org/10.1182/blood.2019001385

Published: 2019

Includes: Supplemental data

Journal Articles

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Jennifer M. O’Sullivan, Angela Hamblin, Christina Yap, Sonia Fox, Rebecca Boucher, Anesh Panchal, Samah Alimam, Helene Dreau, Kieran Howard, Pauline Ware, Nicholas C. P. Cross, Mary Frances McMullin, Claire N. Harrison, Adam J. Mead

Blood (2019) 134 (23): 2107–2111.

https://doi.org/10.1182/blood.2019001861

Published: 2019

Includes: Supplemental data

Journal Articles

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Blood (2017) 130 (17): 1889–1897.

https://doi.org/10.1182/blood-2017-05-785790

Published: 2017

Includes: Supplemental data

Journal Articles

Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers

Mohamad Jawhar, Juliana Schwaab, Nicole Naumann, Hans-Peter Horny, Karl Sotlar, Torsten Haferlach, Georgia Metzgeroth, Alice Fabarius, Peter Valent, Wolf-Karsten Hofmann, Nicholas C. P. Cross, Manja Meggendorfer, Andreas Reiter

Blood (2017) 130 (2): 137–145.

https://doi.org/10.1182/blood-2017-01-764423

Published: 2017

Journal Articles

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Blood (2015) 125 (12): 1857–1865.

https://doi.org/10.1182/blood-2014-10-607341

Published: 2015

Journal Articles

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Chan Y. Cheah, Kate Burbury, Jane F. Apperley, Francoise Huguet, Vincenzo Pitini, Martine Gardembas, David M. Ross, Donna Forrest, Philippe Genet, Philippe Rousselot, Nigel Patton, Graeme Smith, Cynthia E. Dunbar, Sawa Ito, Ricardo C. T. Aguiar, Olatoyosi Odenike, Alla Gimelfarb, Nicholas C. P. Cross, John F. Seymour

Blood (2014) 123 (23): 3574–3577.

https://doi.org/10.1182/blood-2014-02-555607

Published: 2014

Journal Articles

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Blood (2013) 122 (22): 3616–3627.

https://doi.org/10.1182/blood-2013-08-518886

Published: 2013

Includes: Supplemental data

Journal Articles

Comprehensive mutational profiling in advanced systemic mastocytosis

Blood (2013) 122 (14): 2460–2466.

https://doi.org/10.1182/blood-2013-04-496448

Published: 2013

Includes: Supplemental data

Journal Articles

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

David G. Oscier, Matthew J. J. Rose-Zerilli, Nils Winkelmann, David Gonzalez de Castro, Belen Gomez, Jade Forster, Helen Parker, Anton Parker, Anne Gardiner, Andrew Collins, Monica Else, Nicholas C. P. Cross, Daniel Catovsky, Jonathan C. Strefford

Blood (2013) 121 (3): 468–475.

https://doi.org/10.1182/blood-2012-05-429282

Published: 2013

Includes: Supplemental data

Journal Articles

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

Blood (2012) 119 (14): 3211–3218.

https://doi.org/10.1182/blood-2011-12-400994

Published: 2012

Includes: Supplemental data

Journal Articles

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

Joannah Score, Claire Hidalgo-Curtis, Amy V. Jones, Nils Winkelmann, Alison Skinner, Daniel Ward, Katerina Zoi, Thomas Ernst, Frank Stegelmann, Konstanze Döhner, Andrew Chase, Nicholas C. P. Cross

Blood (2012) 119 (5): 1208–1213.

https://doi.org/10.1182/blood-2011-07-367243

Published: 2012

Includes: Supplemental data

Journal Articles

EZH2 mutational status predicts poor survival in myelofibrosis

Paola Guglielmelli, Flavia Biamonte, Joannah Score, Claire Hidalgo-Curtis, Francisco Cervantes, Margherita Maffioli, Tiziana Fanelli, Thomas Ernst, Nils Winkelman, Amy V. Jones, Katerina Zoi, Andreas Reiter, Andrew Duncombe, Laura Villani, Alberto Bosi, Giovanni Barosi, Nicholas C. P. Cross, Alessandro M. Vannucchi

Blood (2011) 118 (19): 5227–5234.

https://doi.org/10.1182/blood-2011-06-363424

Published: 2011

Includes: Supplemental data

Journal Articles

Response of ETV6-FLT3 –positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3

Christoph Walz, Philipp Erben, Michael Ritter, Adrian Bloor, Georgia Metzgeroth, Nick Telford, Claudia Haferlach, Torsten Haferlach, Stefan Gesk, Joannah Score, Wolf-Karsten Hofmann, Andreas Hochhaus, Nicholas C. P. Cross, Andreas Reiter

Blood (2011) 118 (8): 2239–2242.

https://doi.org/10.1182/blood-2011-03-343426

Published: 2011

Includes: Supplemental data

Journal Articles

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Simona Soverini, Andreas Hochhaus, Franck E. Nicolini, Franz Gruber, Thoralf Lange, Giuseppe Saglio, Fabrizio Pane, Martin C. Müller, Thomas Ernst, Gianantonio Rosti, Kimmo Porkka, Michele Baccarani, Nicholas C. P. Cross, Giovanni Martinelli

Blood (2011) 118 (5): 1208–1215.

https://doi.org/10.1182/blood-2010-12-326405

Published: 2011

Journal Articles

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease

Christian Elling, Philipp Erben, Christoph Walz, Marie Frickenhaus, Mirle Schemionek, Martin Stehling, Hubert Serve, Nicholas C. P. Cross, Andreas Hochhaus, Wolf-Karsten Hofmann, Wolfgang E. Berdel, Carsten Müller-Tidow, Andreas Reiter, Steffen Koschmieder

Blood (2011) 117 (10): 2935–2943.

https://doi.org/10.1182/blood-2010-05-286757

Published: 2011

Journal Articles

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Blood (2010) 116 (22): e111–e117.

https://doi.org/10.1182/blood-2010-06-291641

Published: 2010

Includes: Supplemental data

Journal Articles

Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression

Simona Soverini, Angela Poerio, Alberto Ferrarini, Ilaria Iacobucci, Marco Sazzini, Joannah Score, PhD, Enrico Giacomelli, Luciano Xumerle, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Marilina Amabile, Gianantonio Rosti, Michele Baccarani, Nicholas C. P. Cross, MD, Massimo Delledonne, Giovanni Martinelli

Blood (2010) 116 (21): 885.

https://doi.org/10.1182/blood.V116.21.885.885

Published: 2010

Journal Articles

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Martin C. Müller, MD, Umang Munjal, PhD, Philipp Erben, MD, Thomas Lion, MD, PhD, Gerlinde Mitterbauer-Hohendanner, MD, Hakim El Housni, MD, Nancy Boeckx, Renata Zadro, MD, PhD, Jiri Mayer, MD, PhD, Peter Rohon, MD, Jana Rulcova, PhD, Lykke Grubach, Kadri Raudsepp, MD, Veli Kairisto, MD, PhD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, MD, Sandrine Hayette, MD, Jean Gabert, MD, Jean-Michel Cayuela, MD, PhD, Christian Thiede, Lars Galonska, MD, Heike Pfeifer, MD, Carsten Hirt, MD, Philippe Schafhausen, MD, Nils von Neuhoff, PhD, Martin Roskos, MD, Christiane Pott, MD, Thoralf Lange, MD, Georg Hess, MD, Susanne Schnittger, PhD, Annika Dufour, MD, Steffen Koschmieder, MD, Frank Stegelmann, MD, Katerina Zoi, MD, PhD, Kostas Stamatopoulos, Hajnalka Andrikovics, MD, PhD, Tali Tohami, MD, PhD, Giovanni Martinelli, MD, Barbara Izzo, PhD, Enrico Gottardi, MD, Mindaugas Stoskus, Dag Andre Nymoen, MD, Tomasz Sacha, MD, Joana Diamond, MD, PhD, Rodica Talmaci, PhD, Andrey Misyurin, MD, Michael V. Dubina, MD, Tadej Pajic, MD, PhD, Josep F. Nomdedeu, MD, Dolors Colomer, MD, PhD, Gisela Barbany-Bustinza, MD, Hans Ehrencrona, MD, Elisabeth Oppliger Leibundgut, PhD, Jeroen Janssen, MD, Vincent H. J. van der elden, MD, Peter J.M. Valk, MD, PhD, Ugur Ozbek, MD, PhD, Lihui Wang, Gareth Gerrard, PhD, Helen E White, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Rüdiger Hehlmann, MD, Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Nicholas C. P. Cross, PhD

Blood (2010) 116 (21): 893.

https://doi.org/10.1182/blood.V116.21.893.893

Published: 2010

NARROW

The SF3B1 K666 Hotspot Mutation Confers Unfavourable Disease Risk across Major Myeloid Neoplasm Subgroups

Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Comprehensive mutational profiling in advanced systemic mastocytosis

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

EZH2 mutational status predicts poor survival in myelofibrosis

Response of ETV6-FLT3 –positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only